What is Emyria’s Empax program?

Emyria’s Empax program is a clinically validated therapy model designed to support individuals with post-traumatic stress disorder (PTSD) using psychedelic-assisted treatment in an insurer-backed framework.

Where is Emyria currently offering treatment?

The company has launched its first program in Perth and is preparing to expand interstate, beginning with Brisbane.

Why is Emyria’s expansion significant for mental health care?

The expansion highlights a scalable and reimbursed treatment model, addressing the growing demand for mental health services in Australia while ensuring affordability through insurer support.

Emyria Expands Empax PTSD Care Program with Perth Launch and National Growth Plans

3 min read | August 26, 2025 12:40 PM AEST | By Team Kalkine Media

Google News:

Emyria Expands Empax PTSD Care Program with Perth Launch and National Growth Plans — Image source: Shutterstock

Perth Clinic Launch Marks a Milestone

The Perth-based clinic is the first in the country to offer psychedelic-assisted therapy for PTSD under a private health insurance program. Backed by insurer funding, the model reduces financial barriers for eligible patients while validating Emyria’s clinical approach. The company views this development as a foundation for creating a national blueprint for future expansions.

With treatment demand rapidly growing, the Perth facility is already working toward expanding its workforce, including psychiatrists and therapists, to ensure more patients can access care. This momentum provides Emyria with strong confidence in replicating the program across the country.

Strategic Expansion Beyond Perth

Emyria is preparing for the next phase of growth with the establishment of an interstate clinic at the Avive Clinic in Brisbane. By leveraging partnerships with established hospitals, the company aims to reduce upfront capital requirements and accelerate its rollout.

This expansion strengthens Emyria’s position as an emerging leader in evidence-based, insurer-supported mental healthcare, with a focus on making its services accessible to a wider patient population across the nation.

Addressing Australia’s Mental Health Challenge

Mental health remains one of the most pressing chronic health issues in Australia. PTSD, in particular, affects a considerable portion of the population and continues to place significant strain on the country’s healthcare system.

Emyria’s Empax platform, which combines clinical validation with a data-driven framework, is designed to provide consistent and scalable treatment options. By working closely with insurers, regulators, and healthcare providers, the company is shaping a model that could set new benchmarks in accessible mental health support.

Frequently Asked Questions

What is Emyria’s Empax program?
Emyria’s Empax program is a clinically validated therapy model designed to support individuals with post-traumatic stress disorder (PTSD) using psychedelic-assisted treatment in an insurer-backed framework.
Where is Emyria currently offering treatment?
The company has launched its first program in Perth and is preparing to expand interstate, beginning with Brisbane.
Why is Emyria’s expansion significant for mental health care?
The expansion highlights a scalable and reimbursed treatment model, addressing the growing demand for mental health services in Australia while ensuring affordability through insurer support.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.